FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Adrian Senderowicz

Research Profile

Chemicals & Drugs

Physiology

Cell Cycle

Disorders

Procedures

Anatomy

Tumor Cells, Cultured

Living Beings

Mouse

Concepts & Ideas

Co-author Network

Publications

TOP 3
Adrian M Senderowicz
Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
Paola Rojas; Fernando Benavides; Jorge Blando; Carlos Perez; Kim Cardenas; Ellen R Richie; Erik S Knudsen; David G Johnson; Adrian M Senderowicz; Marcelo L Rodriguez-Puebla; Claudio J Conti
Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).
Everardo Macias; Paula L Miliani de Marval; Adriana De Siervi; Claudio J Conti; Adrian M Senderowicz; Marcelo L Rodriguez-Puebla
CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Adrian Senderowicz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Adrian M Senderowicz
Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1719-25.
2009: Paola Rojas; Fernando Benavides; Jorge Blando; Carlos Perez; Kim Cardenas; Ellen R Richie; Erik S Knudsen; David G Johnson; Adrian M Senderowicz; Marcelo L Rodriguez-Puebla; Claudio J Conti
Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).
Molecular carcinogenesis 2009;48(6):508-16.
2008: Everardo Macias; Paula L Miliani de Marval; Adriana De Siervi; Claudio J Conti; Adrian M Senderowicz; Marcelo L Rodriguez-Puebla
CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development.
The American journal of pathology 2008;173(2):526-35.
2008: José Luis Oliva; M Cecilia Caino; Adrian M Senderowicz; Marcelo G Kazanietz
S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells.
The Journal of biological chemistry 2008;283(9):5466-76.
2008: Everardo Macias; Paula L Miliani de Marval; Adrian M Senderowicz; John Cullen; Marcelo L Rodriguez-Puebla
Expression of CDK4 or CDK2 in mouse oral cavity is retained in adult pituitary with distinct effects on tumorigenesis.
Cancer research 2008;68(1):162-71.
2007: Adrian M Senderowicz; John R Johnson; R Sridhara; Paul Zimmerman; Robert Justice; Richard Pazdur
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Oncology (Williston Park, N.Y.) 2007;21(14):1696-706; discussion 1706-9, 1712, 1715.
2005: Martin F Aguero; Maria Facchinetti; Zhanna Sheleg; Adrian M Senderowicz
Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1.
Cancer research 2005;65(8):3364-73.
2005: Utpal Mukhopadhyay; Adrian M Senderowicz; Gerardo Ferbeyre
RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Cancer research 2005;65(7):2872-81.
2005: Adrian M Senderowicz
Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 2005;63():183-206.
2004: Adrian M Senderowicz
Targeting cell cycle and apoptosis for the treatment of human malignancies.
Current opinion in cell biology 2004;16(6):670-8.
2004: Alex Sparreboom; Huachen Chen; Milin R Acharya; Adrian M Senderowicz; Richard A Messmann; Takashi Kuwabara; David J Venzon; Anthony J Murgo; Donna Headlee; Edward A Sausville; William D Figg
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
2004: Maria Facchinetti; Adriana De Siervi; Doreen Toskos; Adrian M Senderowicz
UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Cancer research 2004;64(10):3629-37.
2004: Birgit Hagenauer; Alexandra Maier-Salamon; Theresia Thalhammer; Peter Zöllner; Adrian M Senderowicz; Walter Jäger
Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
Oncology reports 2004;11(5):1069-75.
2004: Anita F W Frijhoff; Claudio J Conti; Adrian M Senderowicz
Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
Molecular carcinogenesis 2004;39(4):183-94.
2004: Adriana De Siervi; Maria Marinissen; Jessica Diggs; Xiao-Fan Wang; Gilles Pages; Adrian M Senderowicz
Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.
Cancer research 2004;64(2):743-50.
2004: Adrian M Senderowicz
Assays for cyclin-dependent kinase inhibitors.
Methods in molecular biology (Clifton, N.J.) 2004;285():69-78.
2003: Walter Jäger; E Gehring; Birgit Hagenauer; Sylvia Aust; Adrian M Senderowicz; Theresia Thalhammer
The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.
International journal of clinical pharmacology and therapeutics 2003;41(12):610-1.
2003: Adrian M Senderowicz
Cell cycle modulators for the treatment of lung malignancies.
Clinical lung cancer 2003;5(3):158-68.
2003: Walter Jäger; E Gehring; Birgit Hagenauer; Sylvia Aust; Adrian M Senderowicz; Theresia Thalhammer
Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).
Life sciences 2003;73(22):2841-54.
2003: MICHELLE RUDEK-RENAUT; Kenneth S. Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna Headlee; Arbuck Susan; Michael C Cox; Anthony J Murgo; Edward A Sausville; William D Figg
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2003: Adrian M Senderowicz
Small-molecule cyclin-dependent kinase modulators.
Oncogene 2003;22(42):6609-20.
2003: David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.
The Journal of biological chemistry 2003;278(32):30339-47.
2003: Adrian M Senderowicz
Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Cancer biology & therapy 2003;2(4 Suppl 1):S84-95.
2003: Adrian M Senderowicz
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Cancer chemotherapy and pharmacology 2003;52 Suppl 1():S61-73.
2003: Tyler Lahusen; Adriana De Siervi; Conrad Kunick; Adrian M Senderowicz
Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential.
Molecular carcinogenesis 2003;36(4):183-94.
2003: Richard A Messmann; Claudio Dansky Ullmann; Tyler Lahusen; Audrey Kalehua; Jason Wasfy; Giovanni Melillo; Ivan Ding; Donna Headlee; William D Figg; Edward A Sausville; Adrian M Senderowicz
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
2003: Suoping Zhai; Edward A Sausville; Adrian M Senderowicz; Yuichi Ando; Donna Headlee; Richard A Messmann; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Eiichi Fuse; William D Figg
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
2003: Adrian M Senderowicz; Tyler Lahusen
Assays for cyclin-dependent kinase inhibitors.
Methods in molecular medicine 2003;85():39-48.
2002: Vyomesh Patel; Tyler Lahusen; Chidchanop Leethanakul; Tadashi Igishi; Marcus Kremer; Leticia Quintanilla-Martinez; John F Ensley; Edward A Sausville; J Silvio Gutkind; Adrian M Senderowicz
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3549-60.
2002: Adrian M Senderowicz
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Hematology/oncology clinics of North America 2002;16(5):1229-53.
2002: Antoinette R Tan; Donna Headlee; Richard A Messmann; Edward A Sausville; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
2002: Suoping Zhai; Adrian M Senderowicz; Edward A Sausville; William D Figg
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy 2002;36(5):905-11.
2002: Vyomesh Patel; Tyler Lahusen; Terence Sy; Edward A Sausville; J Silvio Gutkind; Adrian M Senderowicz
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Cancer research 2002;62(5):1401-9.
2002: Adrian M Senderowicz
Role of cell cycle control and cyclin-dependent kinases in breast cancer.
Breast disease 2002;15():33-52.
2002: Adrian M Senderowicz
Cyclin-dependent kinases as targets for cancer therapy.
Cancer chemotherapy and biological response modifiers 2002;20():169-96.
2002: Adrian M Senderowicz
The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
The oncologist 2002;7 Suppl 3():12-9.
2002: Anita F W Frijhoff; Claudio J Conti; Adrian M Senderowicz
Second symposium of novel molecular targets for cancer therapy.
The oncologist 2002;7 Suppl 3():1-3.
2001: T Bachrich; Theresia Thalhammer; Walter Jäger; Petra Haslmayer; B Alihodzic; S Bakos; Eva Hitchman; Adrian M Senderowicz; Edward Penner
Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.
Hepatology (Baltimore, Md.) 2001;33(5):1053-9.
2001: Edward A Sausville; Arbuck Susan; Richard A Messmann; Donna Headlee; Kenneth S. Bauer; Richard M Lush; Anthony J Murgo; William D Figg; Tyler Lahusen; S Jaken; X Jing ; M Roberge; Eiichi Fuse; Takashi Kuwabara; Adrian M Senderowicz
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
2001: Birgit Hagenauer; Alexandra Salamon; Theresia Thalhammer; Olaf Kunert; Ernst Haslinger; P Klingler; Adrian M Senderowicz; Edward A Sausville; Walter Jäger
In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):407-14.
2001: Adrian M Senderowicz
Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Cancer chemotherapy and biological response modifiers 2001;19():165-88.
2001: Adrian M Senderowicz
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Leukemia 2001;15(1):1-9.
2001: Robert W Robey; Wilma Y Medina-Pérez; K Nishiyama; Tyler Lahusen; K Miyake; Thomas Litman; Adrian M Senderowicz; Douglas Ross; Susan E Bates
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(1):145-52.
2000: Adrian M Senderowicz
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Oncogene 2000;19(56):6600-6.
2000: Maryse Leost; Christiane Schultz; Andreas Link; Y Z Wu; J Biernat; Eva-Maria Mandelkow; James A Bibb; Gretchen L Snyder; Paul Greengard; Daniel W Zaharevitz; Rick Gussio; Adrian M Senderowicz; Edward A Sausville; Conrad Kunick; Laurent Meijer
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
European journal of biochemistry / FEBS 2000;267(19):5983-94.
2000: Victor A Sandor; Adrian M Senderowicz; Susan D Mertins; Dan L Sackett; Edward A Sausville; Mikhail V Blagosklonny; Susan E Bates
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
British journal of cancer 2000;83(6):817-25.
2000: Edward A Sausville; J Johnson; M Alley; Daniel W Zaharevitz; Adrian M Senderowicz
Inhibition of CDKs as a therapeutic modality.
Annals of the New York Academy of Sciences 2000;910():207-21; discussion 221-2.
2000: Richard A Messmann; Ellen S Vitetta; Donna Headlee; Adrian M Senderowicz; William D Figg; John Schindler; D F Michiel; Stephen Creekmore; Seth M Steinberg; David R Kohler; Elaine S Jaffe; Maryalice Stetler-Stevenson; H Chen; Victor Ghetie; Edward A Sausville
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1302-13.
2000: Adrian M Senderowicz; Edward A Sausville
Preclinical and clinical development of cyclin-dependent kinase modulators.
Journal of the National Cancer Institute 2000;92(5):376-87.
2000: Wyndham H Wilson; Lynn Sorbara; William D Figg; E K Mont; Edward A Sausville; Katherine E Warren; FRANK BALIS; Kenneth S. Bauer; Mark Raffeld; Adrian M Senderowicz; Anne Monks
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):415-21.
1999: Giovanni Melillo; Edward A Sausville; K Cloud; Tyler Lahusen; Luigi Varesio; Adrian M Senderowicz
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
Cancer research 1999;59(21):5433-7.
1999: B Carlson; Tyler Lahusen; S Singh; A Loaiza-Perez; P J Worland; R Pestell; C Albanese; Edward A Sausville; Adrian M Senderowicz
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
Cancer research 1999;59(18):4634-41.
1999: Daniel W Zaharevitz; Rick Gussio; Maryse Leost; Adrian M Senderowicz; Tyler Lahusen; Conrad Kunick; Laurent Meijer; Edward A Sausville
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Cancer research 1999;59(11):2566-9.
1999: Edward A Sausville; Daniel W Zaharevitz; Rick Gussio; Laurent Meijer; M Louarn-Leost; Conrad Kunick; R Schultz; Tyler Lahusen; Donna Headlee; Sherman F Stinson; Arbuck Susan; Adrian M Senderowicz
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Pharmacology & therapeutics 1999;82(2-3):285-92.
1999: Adrian M Senderowicz
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Investigational new drugs 1999;17(3):313-20.
1999: Adrian M Senderowicz; R Reid; Donna Headlee; T Abornathy; J Horti; Richard M Lush; Eddie Reed; William D Figg; Edward A Sausville
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1998: Linda Yu; Linda Orlandi; P Wang; M S Orr; Adrian M Senderowicz; Edward A Sausville; R Silvestrini; N Watanabe; Helen Piwnica-Worms; Patrick M O'Connor
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
The Journal of biological chemistry 1998;273(50):33455-64.
1998: Vyomesh Patel; Adrian M Senderowicz; D Pinto; Tadashi Igishi; M Raffeld; Leticia Quintanilla-Martinez; John F Ensley; Edward A Sausville; J Silvio Gutkind
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
The Journal of clinical investigation 1998;102(9):1674-81.
1998: Adrian M Senderowicz; Donna Headlee; Sherman F Stinson; Richard M Lush; N Kalil; L Villalba; K Hill; Seth M Steinberg; William D Figg; AC Tompkins; Arbuck Susan; Edward A Sausville
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
1998: Eiichi Fuse; H Tanii; N Kurata; Hiroyuki Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; Donna Headlee; William D Figg; Arbuck Susan; Adrian M Senderowicz; Edward A Sausville; Shiro Akinaga; Takashi Kuwabara; S Kobayashi
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer research 1998;58(15):3248-53.
1998: Edward A Sausville; R D Lush; Donna Headlee; A C Smith; William D Figg; Arbuck Susan; Adrian M Senderowicz; Eiichi Fuse; H Tanii; Takashi Kuwabara; S Kobayashi
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S54-9.
1998: Walter Jäger; B Zembsch; Peter Wolschann; E Pittenauer; Adrian M Senderowicz; Edward A Sausville; H H Sedlacek; J Graf; Theresia Thalhammer
Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver.
Life sciences 1998;62(20):1861-73.
1998: Nancy A Dawson; William D Figg; Otis W Brawley; Raymond C Bergan; MR Cooper; Adrian M Senderowicz; Donna Headlee; Seth M Steinberg; M Sutherland; Nicholas Patronas; Edward A Sausville; W Marston Linehan; Eddie Reed; Oliver Sartor
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
1997: Adrian M Senderowicz; Ellen S Vitetta; Donna Headlee; Victor Ghetie; Jonathan Uhr; William D Figg; Richard M Lush; Maryalice Stetler-Stevenson; G Kershaw; Douglas W Kingma; Elaine S Jaffe; Edward A Sausville
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
1997: Nancy A Dawson; William D Figg; MR Cooper; Oliver Sartor; Raymond C Bergan; Adrian M Senderowicz; Seth M Steinberg; AC Tompkins; B Weinberger; Edward A Sausville; Eddie Reed; Charles E Myers
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
1997: Ruth Katz; M Quezado; Adrian M Senderowicz; L Villalba; W B Laskin; M Tsokos
An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript.
Human pathology 1997;28(4):502-9.
1996: lee stone; Edward A Sausville; Joseph W Fay; Donna Headlee; Robert H Collins; William D Figg; Maryalice Stetler-Stevenson; V Jain; E S Jaffe; D Solomon; Richard M Lush; Adrian M Senderowicz; Victor Ghetie; J Schindler; J W Uhr; Ellen S Vitetta
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
1996: Edward A Sausville; KL Duncan; Adrian M Senderowicz; J Plowman; Paul A Randazzo; Richard A Kahn; L Malspeis; Michael R Grever
Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.
The cancer journal from Scientific American 1996;2(1):52-8.
1996: William D Figg; Nancy A Dawson; M N Middleman; Otis W Brawley; Richard M Lush; Adrian M Senderowicz; S H Steinberg; AC Tompkins; Eddie Reed; Oliver Sartor
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(6):763-5.
1995: Adrian M Senderowicz; G Kaur; Eduardo Sainz; C Laing; W D Inman; J Rodríguez; P Crews; L Malspeis; Michael R Grever; Edward A Sausville
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
Journal of the National Cancer Institute 1995;87(1):46-51.
1994: michael bubb; Adrian M Senderowicz; Edward A Sausville; KIMBERLY DUNCAN; Edward D Korn
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
The Journal of biological chemistry 1994;269(21):14869-71.